Luís Manso

8.3k total citations · 2 hit papers
153 papers, 3.3k citations indexed

About

Luís Manso is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Luís Manso has authored 153 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 52 papers in Pulmonary and Respiratory Medicine and 37 papers in Cancer Research. Recurrent topics in Luís Manso's work include Cancer Treatment and Pharmacology (42 papers), HER2/EGFR in Cancer Research (41 papers) and Advanced Breast Cancer Therapies (34 papers). Luís Manso is often cited by papers focused on Cancer Treatment and Pharmacology (42 papers), HER2/EGFR in Cancer Research (41 papers) and Advanced Breast Cancer Therapies (34 papers). Luís Manso collaborates with scholars based in Spain, United States and France. Luís Manso's co-authors include Masakazu Toi, Matthew P. Goetz, Mario Campone, Susana Barriga, Shin‐Cheh Chen, Olivier Trédan, Nawel Bourayou, Georgina Garnica Jaliffe, Jens Huober and Ian C. P. Smith and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Luís Manso

144 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luís Manso Spain	22	1.9k	1.6k	802	710	385	153	3.3k
Monica Fornier United States	34	2.5k 1.3×	916 0.6×	722 0.9×	889 1.3×	334 0.9×	110	3.9k
Amanda J. Redig United States	22	1.5k 0.8×	1.5k 0.9×	648 0.8×	1.2k 1.6×	386 1.0×	39	3.1k
Denice Tsao‐Wei United States	33	2.1k 1.1×	919 0.6×	716 0.9×	1.9k 2.6×	202 0.5×	116	4.7k
William Jacot France	34	2.7k 1.4×	1.4k 0.9×	1.2k 1.5×	1.1k 1.5×	347 0.9×	224	4.2k
Gerald W. Prager Austria	32	1.7k 0.9×	802 0.5×	921 1.1×	1.0k 1.4×	136 0.4×	171	3.5k
Rafael López‐López Spain	35	2.2k 1.1×	934 0.6×	1.7k 2.1×	1.8k 2.6×	107 0.3×	242	4.5k
Patrick G. Morris United States	33	2.8k 1.4×	889 0.6×	1.2k 1.5×	1.6k 2.3×	535 1.4×	136	5.2k
Sun‐Young Kong South Korea	32	1.3k 0.7×	498 0.3×	683 0.9×	1.4k 2.0×	150 0.4×	204	3.7k
Daniel Betticher Switzerland	38	2.4k 1.3×	2.2k 1.4×	850 1.1×	1.7k 2.4×	618 1.6×	154	5.5k
Stefania Gori Italy	30	2.0k 1.1×	897 0.6×	694 0.9×	680 1.0×	137 0.4×	180	3.5k

Countries citing papers authored by Luís Manso

Since Specialization

Citations

This map shows the geographic impact of Luís Manso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luís Manso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luís Manso more than expected).

Fields of papers citing papers by Luís Manso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luís Manso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luís Manso. The network helps show where Luís Manso may publish in the future.

Co-authorship network of co-authors of Luís Manso

This figure shows the co-authorship network connecting the top 25 collaborators of Luís Manso. A scholar is included among the top collaborators of Luís Manso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luís Manso. Luís Manso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fidalgo, José Alejandro Pérez, Beatriz Tavira, Eva Guerra, et al.. (2024). Role of the receptor for advanced glycation end products (RAGE) in blood as a potential biomarker for progression to olaparib: A post hoc analysis of patients with platinum-resistant ovarian cancer (PROC) treated in the ROLANDO-GEICO 1601 trial.. Journal of Clinical Oncology. 42(16_suppl). 5566–5566. 1 indexed citations

Manso, Luís, Arántzazu Alfranca, María Dolores Martínez Ruiz, et al.. (2024). Immunome profiling in prostate cancer: a guide for clinicians. Frontiers in Immunology. 15. 1398109–1398109. 2 indexed citations

Manso, Luís, Ignacio A. Romero, Luisa Sánchez‐Lorenzo, et al.. (2024). SEOM-GEICO Clinical Guidelines on cervical cancer (2023). Clinical & Translational Oncology. 26(11). 2771–2782. 7 indexed citations

Sánchez-Bayona, Rodrigo, Ana Sánchez, Isabel Echavarría, et al.. (2024). Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort. Breast Cancer Research and Treatment. 206(3). 551–559. 7 indexed citations

Manso, Luís, et al.. (2023). Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy. International Journal of Gynecological Cancer. 34(2). 277–284. 1 indexed citations

Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations

Tavira, Beatriz, Luís Manso, Ana Santaballa, et al.. (2023). Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study). Clinical Cancer Research. 30(1). 176–186. 6 indexed citations

Moyano, Amanda, José María Duque, Luís Manso, et al.. (2022). Nanozyme-Based Lateral Flow Immunoassay (LFIA) for Extracellular Vesicle Detection. Biosensors. 12(7). 490–490. 14 indexed citations

Carretero-González, Alberto, Marta Hergueta‐Redondo, Sara Sánchez‐Redondo, et al.. (2022). Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis. OncoImmunology. 11(1). 2067944–2067944. 19 indexed citations

10.

Moyano, Amanda, Esther Serrano‐Pertierra, José María Duque, et al.. (2021). Magnetic Lateral Flow Immunoassay for Small Extracellular Vesicles Quantification: Application to Colorectal Cancer Biomarker Detection. Sensors. 21(11). 3756–3756. 22 indexed citations

11.

Goetz, Matthew P., Meena Okera, Hans Wildiers, et al.. (2021). Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. 186(2). 417–428. 34 indexed citations

12.

Manso, Luís, et al.. (2020). Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain. ESMO Open. 5(3). e000828–e000828. 16 indexed citations

13.

Martín, Miguel, José Á. García-Sáenz, Luís Manso, et al.. (2020). Abemaciclib, a CDK4 and CDK6 Inhibitor for the Treatment of Metastatic Breast Cancer. Future Oncology. 16(33). 2763–2778. 12 indexed citations

14.

Manso, Luís, Juan Ignacio Delgado Mingorance, Noelia Martínez-Jáñez, et al.. (2019). Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. The Breast Journal. 25(2). 219–225. 5 indexed citations

15.

Ayala, Francisco, Raquel Andrés, José Á. García-Sáenz, et al.. (2018). SEOM clinical guidelines in early stage breast cancer (2018). Clinical & Translational Oncology. 21(1). 18–30. 47 indexed citations

16.

Redondo, Andrés, Manuel Ramos Vázquez, Luís Manso, et al.. (2018). Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study. OncoTargets and Therapy. Volume 11. 5845–5852. 5 indexed citations

17.

Carretero-González, Alberto, Irene Otero, Lucía Carril-Ajuria, Guillermo de Velasco, & Luís Manso. (2018). Exosomes: Definition, Role in Tumor Development and Clinical Implications. Cancer Microenvironment. 11(1). 13–21. 38 indexed citations

18.

Goetz, Matthew P., Masakazu Toi, Mario Campone, et al.. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology. 35(32). 3638–3646. 1125 indexed citations breakdown →

19.

Salvador, J., Luís Manso, Juan de la Haba-Rodríguez, et al.. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & Translational Oncology. 17(2). 160–166. 10 indexed citations

20.

Arca, Marcello, et al.. (1998). Tamizaje de marcadores para hepatitis B pre y post-vacunación en el hospital de C. del Uruguay, Argentina. Acta bioquímica clínica latinoamericana. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact